Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-0822

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Tartrate–resistant acid phosphatase (TRAP/ ACP5) belongs to the binuclear metallophosphatase family and is present in two… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2019
Review
2019
Belongs to the metabolic disease with the highest incidence rate. The middle-aged and elderly people are the main disease group… Expand
Is this relevant?
2012
2012
Odanacatib (ODN, MK-0822) is an investigational drug under development for the treatment of osteoporosis. A quantitative LC/MS-MS… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
Review
2011
Review
2011
Bone homeostasis is maintained by delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts… Expand
Is this relevant?
Review
2009
Review
2009
Odanacatib (MK-0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under license… Expand
Is this relevant?
2009
2009
An enantioselective synthesis of the Cathepsin K inhibitor odanacatib (MK-0822) 1 is described. The key step involves the novel… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… Expand
Is this relevant?